Denali Therapeutics
DNLI
223 hedge funds and large institutions have $2.61B invested in Denali Therapeutics in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 59 reducing their positions, and 32 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
80% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $750K
47% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 59
25% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 32
3% more funds holding
Funds holding: 217 → 223 (+6)
0.35% more ownership
Funds ownership: 88.53% → 88.89% (+0.35%)
29% less capital invested
Capital invested by funds: $3.69B → $2.61B (-$1.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$18.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$17.1M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$13.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$62.3M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$26.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.5M |
| 4 |
Morgan Stanley
New York
|
-$13.2M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$9.22M |
DNLI Hedge Fund Activity: Q4 2024 in Review
223 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2024, worth a combined $2.61B — down 29% from $3.69B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new DNLI positions and 32 closed out — a net gain of 8 holders — while 87 added to existing stakes and 59 trimmed.
The largest buyer was Vanguard Group, adding an estimated $21.6M. The largest seller was Capital Research Global Investors, cutting an estimated $62.3M.
- 223 institutional investors held Denali Therapeutics (DNLI) as of Q4 2024, up from 217 in Q3 2024.
- Funds reported $2.61B of Denali Therapeutics stock for Q4 2024, down 29% quarter-over-quarter.
- 40 funds opened new Denali Therapeutics positions in Q4 2024 and 32 closed out, a net change of +8 holders.
- The largest Denali Therapeutics buyer in Q4 2024 was Vanguard Group, an estimated $21.6M added.
- The largest Denali Therapeutics seller in Q4 2024 was Capital Research Global Investors, an estimated $62.3M sold.
Based on aggregated 13F filings for Q4 2024.